Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).
1. A method for treating a patient afflicted with breast cancer characterized as having a triple negative phenotype and further characterized as expressing an antigen, said method comprises administering to the patient a therapeutic amount of nanoparticle complexes, said nanoparticle complexes comprising: a) albumin; b) an effective amount of a binding agent having an antigen-binding portion that binds to the antigen so as to provide directional guidance of the nanoparticle complexes to said cancer; and c) an effective amount of paclitaxel; wherein the average size of the nanoparticle complexes is from about 100 nm to about 3.5 μm.
2. The method of claim 1 , wherein said binding agents are arranged on the outside surface of the nanoparticle complexes.
3. The method of claim 1 , wherein the binding agent is an antibody selected from an anti-VEGF antibody, an anti-cancer testis (CT) antigen antibody, an anti-folate receptor alpha (FR-alpha) antibody, an anti-programmed death-ligand 1 (PD-L1) antibody, an anti-programmed cell death protein 1 (PD-1) antibody, an anti-epidermal growth factor receptor (EGFR) antibody, an anti-C-kit antibody, and an anti-basal cytokeratin antibody.
4. The method of claim 3 , wherein the binding agent is the anti-VEGF antibody, and wherein the anti-VEGF antibody is bevacizumab or a biosimilar version thereof.
5. The method of claim 3 , wherein the binding agent is an anti-CT antigen antibody.
6. The method of claim 5 , wherein the CT antigen is selected from TSAG10, a MAGE family member, NY-ESO-1/CTAG1B, CTAG2, PLAC1, and DKKL1.
7. The method of claim 6 , wherein the MAGE family member is selected from MAGEA2B, MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEA9, MAGEA10, and MAGEA12.
8. The method of claim 3 , wherein the binding agent is an anti-basal cytokeratin antibody.
9. The method of claim 8 , wherein the anti-basal cytokeratin antibody is an anti-CK-5 basal cytokeratin antibody, an anti-CK-14 basal cytokeratin antibody, or an anti-CK-17 basal cytokeratin antibody.
10. The method of claim 3 , wherein the binding agent is the anti-PD-L1 antibody, and wherein the anti-PD-L1 antibody is BMS-936559, atezolizumab, durvalumab, or avelumab.
11. The method of claim 3 , wherein the binding agent is the anti-PD-1 antibody, and wherein the anti-PD-1 antibody is nivolumab or pembrolizumab.
12. The method of claim 3 , wherein the binding agent is the anti-EGFR antibody, and wherein the anti-EGFR antibody is cetuximab or panitumumab.
13. The method of claim 1 , wherein the albumin is human serum albumin.
14. The method of claim 13 , wherein the albumin is recombinant human serum albumin.
15. The method of claim 1 , wherein each nanoparticle complex comprises between 100 and 1,000 antibodies.
16. The method of claim 1 , wherein the binding agents are arranged into a substantially single layer of antibodies on all or part of a surface of the nanoparticle complexes.
17. The method of claim 1 , wherein the average size of nanoparticle complexes is from about 800 nm to about 3.5 μm.
18. The method of claim 1 , wherein the average size of the nanoparticle complexes is from about 100 nm to about 1 micron.
19. The method of claim 1 , wherein said nanoparticle complexes have an average size of approximately 160 nm.
20. The method of claim 1 , wherein the cancer cell has not previously been treated with an anti-VEGF antibody.